Zynex has completed the clinical verification trial of its pulse oximeter, NiCO, marking a significant milestone towards the Food and Drug Administration (FDA) clearance. Overseen by Duke ...

Zynex had a return on equity of 13.05% and a net margin of 2.49%. The business had revenue of $49.97 million during the quarter, compared to analyst estimates of $50.83 million.

ENGLEWOOD, Colo., Dec. 5, 2024 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI) ("Zynex", "ZMS", "we" or the "Company"), an innovative medical technology company ...

Zynex (ZYXI) announced highlights from a recent study comparing its NiCO laser pulse oximeter to conventional LED pulse oximeters for the effects of skin pigmentation on SpO2 measurements. Zynex’s ...

Key Insights The projected fair value for Zynex is US$10.75 based on 2 Stage Free Cash Flow to Equity Zynex is... Zynex, Inc. (NASDAQ: ZYXI) ("Zynex", "ZMS", "we" or the "Company"), an innovative ...

GET MORE AI-GENERATED SIGNALS: December 18, 2024, 05:58 am ET, BY Patrick- Contributor, Stock Traders Daily| Editor: Thomas H ...

Zynex (ZYXI) has completed its clinical verification trial for their NiCO pulse oximeter overseen by anesthesiologist Dr. David MacLeod at Duke University. Trial completion is a key milestone ...

Zynex, Inc. operates primarily in the pain management sector, with a growing interest in patient monitoring technologies. The company's business model revolves around developing and marketing medical ...

Zynex, Inc. (NASDAQ: ZYXI) ("Zynex", "ZMS", "we" or the "Company"), an innovative medical technology company specializing in ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...